Abbott India Ltd
NSE:ABBOTINDIA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/B
Price to Book (P/B) ratio compares a company`s market value to its book value. It shows how much investors are paying for each dollar of net assets on the balance sheet.
Price to Book (P/B) ratio compares a company`s market value to its book value. It shows how much investors are paying for each dollar of net assets on the balance sheet.
Valuation Scenarios
If P/B returns to its 3-Year Average (15.8), the stock would be worth ₹29 876.64 (18% upside from current price).
| Scenario | P/B Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 13.4 | ₹25 305 |
0%
|
| 3-Year Average | 15.8 | ₹29 876.64 |
+18%
|
| 5-Year Average | 15.4 | ₹28 994.99 |
+15%
|
| Industry Average | 3.6 | ₹6 713.49 |
-73%
|
| Country Average | 3.3 | ₹6 134.56 |
-76%
|
Forward P/B
Today’s price vs future total equity
Peer Comparison
| Market Cap | P/B | P/E | ||||
|---|---|---|---|---|---|---|
| IN |
A
|
Abbott India Ltd
NSE:ABBOTINDIA
|
541.3B INR | 13.4 | 35.3 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
804.2B USD | 30.3 | 39 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
547.4B USD | 6.7 | 26 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 7.7 | 20.1 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
212.4B GBP | 5.8 | 27.5 | |
| CH |
|
Novartis AG
SIX:NOVN
|
220.1B CHF | 5.9 | 19.5 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
274.6B USD | 5.2 | 15 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD | -58.7 | -83.6 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.2T DKK | 5.9 | 11.1 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
149.3B USD | 1.7 | 19.2 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
115.9B USD | 6.3 | 16.4 |
Market Distribution
| Min | 0 |
| 30th Percentile | 2.1 |
| Median | 3.3 |
| 70th Percentile | 5.5 |
| Max | 4 699.1 |
Other Multiples
Abbott India Ltd
Glance View
Abbott India Ltd., a subsidiary of the global healthcare conglomerate Abbott Laboratories, operates as a key player in India’s pharmaceutical landscape. Nestled in the vibrant, ever-evolving Indian market, Abbott India has carved a niche for itself with a strategic focus on both innovation and localization. Its operations span the development, manufacture, and sale of a wide array of pharmaceutical products. By leveraging Abbott's global expertise and its deep understanding of local market dynamics, the company designs solutions catered to the unique health challenges faced by Indian consumers. Their product portfolio includes a diverse range of proprietary medicines, nutrition products, diagnostics, and branded generics, which address therapeutic areas like cardiology, women's health, gastroenterology, and metabolic disorders. Abbott India’s revenue engine primarily hinges on its extensive distribution networks and its substantial investments in research and development aimed at optimizing treatment paradigms. The company employs a customer-centric approach, working closely with healthcare professionals to ensure the accessibility of its medications across the country. By aligning its operations with the latest trends in healthcare needs and regulatory requirements, Abbott India ensures it remains at the forefront of serving its consumers efficiently. Its commitment to quality and continuous product improvement not only strengthens its market position but also fuels its growth trajectory in the Indian pharmaceutical sector, making it a formidable entity poised for sustained success in a dynamic industry.